SEC Tracker
Get the app

TELA Bio TELA

TELA Bio Bio reports third quarter 2026 results

TELA Bio (TELA) filed an 8-K with the SEC on Nov 10, 2026, 4:05 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Revenue of $19.0 million for Q3 2026
  2. Operating loss decreased by 21% sequentially
  3. Adjusted EBITDA loss decreased by 55% sequentially
  4. Cost reduction initiative to save $17.0 million annually

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when TELA Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.